Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Frequent but nonspecific venous narrowing in paediatric multiple sclerosis.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Food and Drug Administration briefing document for ofatumumab
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Laquinimod
No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis.
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
Current and future drugs for treatment of MS-associated bladder dysfunction.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.

Pages